Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA's Fears Realized: Sponsors Pitching Investors 'Sarepta Model'

Oct 26 2016

• By Derrick Gingery

Related Content

Patients Can't Rescue Sarepta's Eteplirsen

Apr 26 2016

Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?

Sep 21 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Oct 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Accelerated Approval Should Be Less 'Wide Open,' Califf Says

Oct 20 2016

Duchenne Group's Presentation Is Milestone For Patient Involvement

May 02 2016

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Oct 15 2016

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Sep 23 2016

Related Companies

Sarepta Therapeutics, Inc.

PTC Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

United States Rare Diseases Clinical Trials Regulation Drug Approval Standards Business Strategies Drug Review Review Pathway BioPharmaceutical Neurology

More from Rare Diseases

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.